On November 14, the three major indices of Hong Kong stocks collectively adjusted downwards. However, biopharmaceuticals and innovative drug concept stocks experienced a strong rise, with VV Technology surging over 18%, CStone Pharmaceuticals up more than 15%, and Ascletis Pharma increasing by over 12%. On November 10, the National Disease Control and Prevention Administration had mentioned at a press conference that the peak of this year's seasonal flu in China might occur in mid-to-late December and early January. With winter flu entering its high-incidence season, could a rally in pharmaceutical stocks be on the horizon? Could Hong Kong-listed pharmaceutical stocks serve as the 'thermos cup' in winter?